文献速递中毒与环境急症消化、代谢与肾脏急症

技术辅助丁丙诺啡治疗在乡村与非乡村环境中的应用:两项随机临床试验

Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings: Two Randomized Clinical Trials.
PubMed 文献 · JAMA Netw Open · 2023-09-05
一句话结论两项随机临床试验显示,技术辅助丁丙诺啡治疗在乡村与非乡村社区均显著提高阿片类戒断率,并改善治疗依从性与知识。

两项平行、24周随机临床试验于2018年2月1日至2022年6月30日在佛蒙特大学开展,纳入非乡村(试验1)与乡村(试验2)社区未治疗阿片类使用障碍成人各50例,随机接受技术辅助丁丙诺啡(TAB)或对照。TAB组每月两次就诊服药并获带回家剂量,接受夜间交互式语音应答(IVR)电话、随机回拨及iPad提供的HIV、丙肝与过量教育;对照组获社区资源指南及联系协助。主要终点为每月评估中生化验证的非法阿片类戒断,TAB组在两项试验所有时间点均显著优于对照:试验1为85.3%(128/150;95%CI 70.7%-93.3%)vs 24.0%(36/150;95%CI 13.6%-38.8%),试验2为88.0%(132/150;95%CI 72.1%-95.4%)vs 21.3%(32/150;95%CI 11.4%-36.5%)。TAB组双月给药访视戒断率亦高(试验1 83.0%,95%CI 67.0%-92.0%;试验2 88.0%,95%CI 71.0%-95.0%),治疗依从性良好(丁丙诺啡给药约99%、每日IVR电话93%、随机回拨92%),随机回拨时187份尿样中183份(97.9%)非法阿片类阴性,iPad教育带来HIV、HCV与过量知识的显著持续提升。

要点

  • TAB组非法阿片类戒断率在两项试验所有时间点均显著高于对照:试验1 85.3% vs 24.0%,试验2 88.0% vs 21.3%。
  • TAB组双月给药访视戒断率亦高:试验1 83.0%(95%CI 67.0%-92.0%),试验2 88.0%(95%CI 71.0%-95.0%)。
  • 治疗依从性良好:丁丙诺啡给药约99%、每日IVR电话93%、随机回拨92%;随机回拨尿样97.9%(183/187)非法阿片类阴性。
  • iPad提供的HIV、HCV与过量教育带来显著且持续的知识提升。
  • 作者结论:TAB疗效在此前研究基础上延长至24周,并扩展至乡村社区患者。

适用人群与场景

  • 非乡村社区(试验1)或乡村社区(试验2)的未治疗阿片类使用障碍成人,各50例。
  • 试验1参与者平均(SD)年龄40.6(13.1)岁,28例(56.0%)男性;试验2平均(SD)年龄40.3(10.8)岁,30例(60.0%)男性。

处置流程与药物剂量

  • TAB组:每月两次就诊吞服药物并经计算机化设备获得带回家剂量,接受夜间IVR电话、IVR生成的随机回拨,以及iPad提供的HIV、HCV与过量教育。
  • 对照组:获得社区资源指南及联系资源的协助;所有参与者获得减害用品并完成每月评估。

研究设计与关键结果

  • 设计:两项平行、24周随机临床试验,2018年2月1日至2022年6月30日在佛蒙特大学开展,每项试验50例随机分入TAB或对照。
  • 主要终点:每月评估中生化验证的非法阿片类戒断,TAB组在两项试验所有时间点均显著高于对照:试验1 85.3%(128/150;95%CI 70.7%-93.3%)vs 24.0%(36/150;95%CI 13.6%-38.8%);试验2 88.0%(132/150;95%CI 72.1%-95.4%)vs 21.3%(32/150;95%CI 11.4%-36.5%)。
  • 次要终点:TAB组双月给药访视戒断率试验1 83.0%(95%CI 67.0%-92.0%)、试验2 88.0%(95%CI 71.0%-95.0%);治疗依从性两项试验相近,丁丙诺啡给药约99%、每日IVR电话93%、随机回拨92%;随机回拨时187份尿样中183份(97.9%)非法阿片类阴性。
  • iPad教育:与HIV、HCV与过量知识显著且持续增加相关。

证据类型、等级与局限

  • 证据类型:两项随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在非乡村与乡村社区未治疗阿片类使用障碍成人中,TAB方案可显著提高生化验证的非法阿片类戒断率并保持高治疗依从性。
  • 作者认为,TAB疗效在此前研究基础上延长至24周,并扩展至乡村社区患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Expansion of opioid use disorder treatment is needed, particularly in rural communities.

OBJECTIVE: To evaluate technology-assisted buprenorphine (TAB) efficacy (1) over a longer period than previously examined, (2) with the addition of overdose education, and (3) among individuals residing in rural communities.

DESIGN, SETTING, AND PARTICIPANTS: Two parallel, 24-week randomized clinical trials were conducted at the University of Vermont between February 1, 2018, and June 30, 2022. Participants were adults with untreated opioid use disorder from nonrural (trial 1) or rural (trial 2) communities. These trials are part of a programmatic effort to develop TAB protocols to improve treatment availability in underserved areas.

INTERVENTIONS: Within each trial, 50 participants were randomized to TAB or control conditions. Participants in the TAB group completed bimonthly visits to ingest medication and receive take-home doses via a computerized device. They received nightly calls via an interactive voice response (IVR) system, IVR-generated random call-backs, and iPad-delivered HIV, hepatitis C virus (HCV), and overdose education. Control participants received community resource guides and assistance with contacting resources. All participants received harm reduction supplies and completed monthly assessments.

MAIN OUTCOMES AND MEASURES: The primary outcome was biochemically verified illicit opioid abstinence across monthly assessments. Secondary outcomes included self-reported opioid use in both groups and abstinence at bimonthly and random call-back visits, treatment adherence, satisfaction, and changes in HIV, HCV, and overdose knowledge among TAB participants.

RESULTS: Fifty individuals (mean [SD] age, 40.6 [13.1] years; 28 [56.0%] male) participated in trial 1, and 50 (mean [SD] age, 40.3 [10.8] years; 30 [60.0%] male) participated in trial 2. Participants in the TAB group achieved significantly greater illicit opioid abstinence vs controls at all time points in both trial 1 (85.3% [128 of 150]; 95% CI, 70.7%-93.3%; vs 24.0% [36 of 150]; 95% CI, 13.6%-38.8%) and trial 2 (88.0% [132 of 150]; 95% CI, 72.1%-95.4%; vs 21.3% [32 of 150]; 95% CI, 11.4%-36.5%). High abstinence rates were also observed at TAB participants' bimonthly dosing visits (83.0% [95% CI, 67.0%-92.0%] for trial 1 and 88.0% [95% CI, 71.0%-95.0%] for trial 2). Treatment adherence was favorable and similar between trials (with rates of approximately 99% for buprenorphine administration, 93% for daily IVR calls, and 92% for random call-backs), and 183 of 187 urine samples (97.9%) tested negative for illicit opioids at random call-backs. iPad-delivered education was associated with significant and sustained increases in HIV, HCV, and overdose knowledge.

CONCLUSIONS AND RELEVANCE: In these randomized clinical trials of TAB treatment, demonstration of efficacy was extended to a longer duration than previously examined and to patients residing in rural communities.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03420313.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Sigmon SC, Peck KR, Batchelder SR, et al. Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings: Two Randomized Clinical Trials. JAMA Netw Open. 2023. PMID: 37755833. doi:10.1001/jamanetworkopen.2023.31910

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。